title: Inhibitory effects of telmisartan on culture and proliferation of and Kv1.3 potassium channel expression in peripheral blood CD4+ T lymphocytes from Xinjiang Kazakh patients with hypertension.
abstract: BACKGROUND
  Activation of T lymphocytes, for which potassium channels are essential, is involved in the development of hypertension. In this study, we explored the inhibitory effects of telmisartan on the culture and proliferation of and Kv1.3 potassium channel expression in peripheral blood CD4+T lymphocytes derived from Xinjiang Kazakh patients with hypertension.
  
  
  METHODS
  CD4+T-cell samples from hypertensive Kazakh patients and healthy Kazakh people were divided into healthy control, case control, telmisartan, and 4-aminopytidine groups. Changes in the expression levels of interleukin (IL)-6 and IL-17 in the blood of the healthy control and case control subjects were detected by enzyme-linked immunosorbent assay. Peripheral blood CD4+T lymphocytes were first activated and proliferated in vitro and then incubated for 0, 24, and 48 h under various treatment conditions. Thereafter, changes in CD4+T-lymphocytic proliferation were determined using Cell Counting Kit-8 and microscope photography. Changes in messenger RNA (mRNA) and protein expression of the Kv1.3 potassium channel in CD4+T lymphocytes were detected using real-time quantitative polymerase chain reaction and Western blots, respectively.
  
  
  RESULTS
  The IL-6 and IL-17 expression levels were significantly higher in the blood of the hypertensive Kazakh patients than in the healthy Kazakh people. Telmisartan inhibited T-lymphocytic proliferation, as well as the mRNA and protein expression of the Kv1.3 potassium channel in CD4+T lymphocytes, and the inhibitory effects were time-dependent, with the strongest inhibition observed after 48 h and significantly weaker inhibition observed after 24 h of treatment.
  
  
  CONCLUSIONS
  Telmisartan may potentially regulate hypertensive inflammatory responses by inhibiting T-lymphocytic proliferation and Kv1.3 potassium channel expression in CD4+T lymphocytes.
authors.affiliation: Heart Centre, First Affiliated Hospital of Xinjiang Medical University, China.
authors.forename: Sha-Sha
authors.initials: SS
authors.lastname: Huang
authors.affiliation: Heart Centre, First Affiliated Hospital of Xinjiang Medical University, China.
authors.forename: Qiu-Bing
authors.initials: QB
authors.lastname: Zhang
authors.affiliation: Heart Centre, First Affiliated Hospital of Xinjiang Medical University, China.
authors.forename: Qing-Yan
authors.initials: QY
authors.lastname: Yuan
authors.affiliation: Heart Centre, First Affiliated Hospital of Xinjiang Medical University, China.
authors.forename: Si-Li
authors.initials: SL
authors.lastname: He
authors.affiliation: Heart Centre, First Affiliated Hospital of Xinjiang Medical University, China 13999867798@163.com.
authors.forename: Yuan-Ming
authors.initials: YM
authors.lastname: Zhang
mesh_terms: D001562:Benzimidazoles / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D015153:Blotting, Western; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000473:pathology*; D016022:Case-Control Studies; D049109:Cell Proliferation / Q000187:drug effects; D048430:Cell Shape / Q000187:drug effects; D002478:Cells, Cultured; D002681:China; D003710:Demography; D005006:Ethnicity; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000276:immunology* / Q000473:pathology*; D020381:Interleukin-17 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D051664:Kv1.3 Potassium Channel / Q000235:genetics / Q000378:metabolism*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D000077333:Telmisartan
chemical_list: D001562:Benzimidazoles; D001565:Benzoates; C508600:IL6 protein, human; D020381:Interleukin-17; D015850:Interleukin-6; D051664:Kv1.3 Potassium Channel; D012333:RNA, Messenger; D000077333:Telmisartan
keywords: CD4+ T Lymphocytes; Kv1.3 potassium channel; Xinjiang Kazakh; essential hypertension; telmisartan